Exelixis (EXEL) announced that it had obtained FDA approval for its drug cabometyx for previously treated patients with hepatocellular carcinoma (liver cancer). This latest approval expands the market opportunity of this drug in the U.S. market. This is good news on top of previous news in which cabometyx was approved for the same indication in Europe last year. The problem is that Exelixis still has a host of competitors to get through to obtain market share for this cancer drug in this liver cancer indication.
FDA Approval
Exelixis was able to obtain FDA